phone: + 353 91 386 660

email: brendan.mclaughlin@capsosmedical.com

Capsos Medical have patented technology for a device to facilitate the safe and controlled crossing of the calcified cap of chronic total occlusions through the true lumen.

CURRENT TREATMENT OF CTO’s

The treatment of chronic total occlusions (CTO’s) is challenging for the endovascular specialist. Historically, long total occlusions were treated with bypass surgery. In recent years, complex tools such as Lasers, Radiofrequency Catheters and high speed cutters have been introduced to reopen these hard fibrous blockages. While successful they are complex and have associated expensive capital equipment costs.

OUR DEVICE - CapBuster

Capsos Medical have developed a balloon catheter & guidewire combination device (CapBuster), that provides Physicians with an easy-to-use and innovative solution.

It will be used to re-open the most resistant occlusions where a calcified cap has formed on the surface of the blockage.

 

CapBuster uses the mechanical advantage of a screw-thread and uses standard tools and techniques used in all angioplasties in every hospital cath lab in the world.

 

It provides a simple, fast, cost-effective, low risk method with a high degree of penetration through the calcified blockage to treat CTO’s with minimal training required for  the Physician and no capital equipment required for the hospital.

CapBuster utilizes the mechanical advantage of a screw-thread to apply gradual, sustained pressure using the balloon catheter as an anchor to hold the device in place.

The benefits of CapBuster include a simple, low cost and mechanically superior method which produces over 5 times the peak penetration of the closest competitor, with no energy lost at the tip. The device can be progressed forward, or reversed out at anytime, thus giving control to the physician.

 

It is a disruptive technology that improves patient quality of life and has the potential to eliminate the need for ineffective and expensive alternatives such as medication and bypass surgery which are currently the most common ways to treat CTO’s.

CTOs are encountered in approximately 20% to 30% of all patients who undergo angiography. This equates to approximately 1.8m CTO’s. 50% of coronary CTO’s are treated with medication, 40% receive bypass surgery, and only 10% are treated using minimally invasive techniques. This is because of problems with existing devices that either do not work or are very expensive and need a lot of training with high skill levels required by the Clinician, with associated levels of high risk.

 

The  CapBuster is also suitable for many other angioplasties including partial blockages and

in-stent restenosis.

Penetrating CTO's is often described as the final frontier of angioplasty, CapBuster can penetrate the CTO in a safe, slow and controlled manner.

CONTACT US

CONTACT INFO

phone: + 353 91 386 660

address: Capsos Medical, Innovation in Business Centre, GMIT, Dublin Road, Galway, H91 DCH9, Ireland.

Submitting Form...

The server encountered an error.

Form received.

If you have any question, please contact Us:

All rights reserved Copyright © 2015 Capsos Medical